Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT

Andrew C. Dietz; Sharon A. Savage; Adrianna Vlachos; Parinda A. Mehta; Dorine Bresters; Jakub Tolar; Carmem Bonfim; Jean Hugues Dalle; Josu de la Fuente; Roderick Skinner; Farid Boulad; Christine N. Duncan; K. Scott Baker; Michael A. Pulsipher; Jeffrey M. Lipton; John E. Wagner; Blanche P. Alter

doi:10.1016/j.bbmt.2017.05.022

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT

Andrew C. Dietz, Sharon A. Savage, Adrianna Vlachos, Parinda A. Mehta, Dorine Bresters, Jakub Tolar, Carmem Bonfim, Jean Hugues Dalle, Josu de la Fuente, Roderick Skinner, Farid Boulad, Christine N. Duncan, K. Scott Baker, Michael A. Pulsipher, Jeffrey M. Lipton, John E. Wagner, Blanche P. Alter

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Patients with inherited bone marrow failure syndromes (IBMFS), such as Fanconi anemia (FA), dyskeratosis congenita (DC), or Diamond Blackfan anemia (DBA), can have hematologic manifestations cured through hematopoietic cell transplantation (HCT). Subsequent late effects seen in these patients arise from a combination of the underlying disease, the pre-HCT therapy, and the HCT process. During the international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium on late effects screening and recommendations following allogeneic hematopoietic cell transplantation for immune deficiency and nonmalignant hematologic diseases held in Minneapolis, Minnesota in May 2016, a half-day session was focused specifically on the unmet needs for these patients with IBMFS. This multidisciplinary group of experts in rare diseases and transplantation late effects has already published on the state of the science in this area, along with discussion of an agenda for future research. This companion article outlines consensus disease-specific long-term follow-up screening guidelines for patients with IMBFS.

Original language	English (US)
Pages (from-to)	1422-1428
Number of pages	7
Journal	Biology of Blood and Marrow Transplantation
Volume	23
Issue number	9
DOIs	https://doi.org/10.1016/j.bbmt.2017.05.022
State	Published - Sep 2017

Bibliographical note

Funding Information:
Financial disclosure: This work was supported in part by grants from the National Institutes of Health (1R13CA159788-01, to M.A.P. and K.S.B.; U01HL069254, to M.A.P.; R01 CA078938, to K.S.B.; and 5R01HL079571, to J.M.L. and A.V.), the Pediatric Blood and Marrow Transplant Consortium, and St. Baldrick's Foundation (U01HL069254, to M.A.P.). B.P.A. and S.A.S. are supported by the Intramural Research Program of the National Cancer Institute. The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding.

Funding Information:
Financial disclosure: This work was supported in part by grants from the National Institutes of Health ( 1R13CA159788-01 , to M.A.P. and K.S.B.; U01HL069254 , to M.A.P.; R01 CA078938 , to K.S.B.; and 5R01HL079571 , to J.M.L. and A.V.), the Pediatric Blood and Marrow Transplant Consortium, and St. Baldrick's Foundation (U01HL069254, to M.A.P.). B.P.A. and S.A.S. are supported by the Intramural Research Program of the National Cancer Institute . The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: J.E.W. and B.P.A. contributed equally to this work.

Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation

Keywords

Diamond Blackfan anemia
Dyskeratosis congenita
Fanconi anemia
Inherited bone marrow failure syndromes
Late effects
Pediatric allogeneic hematopoietic cell transplant

Publisher link

10.1016/j.bbmt.2017.05.022

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565711

Find It

Find It at U of M Libraries

Fingerprint

Dive into the research topics of 'Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT'. Together they form a unique fingerprint.

Cite this

Dietz, A. C., Savage, S. A., Vlachos, A., Mehta, P. A., Bresters, D., Tolar, J., Bonfim, C., Dalle, J. H., de la Fuente, J., Skinner, R., Boulad, F., Duncan, C. N., Baker, K. S., Pulsipher, M. A., Lipton, J. M., Wagner, J. E., & Alter, B. P. (2017). Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biology of Blood and Marrow Transplantation, 23(9), 1422-1428. https://doi.org/10.1016/j.bbmt.2017.05.022

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes : Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. / Dietz, Andrew C.; Savage, Sharon A.; Vlachos, Adrianna et al.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 9, 09.2017, p. 1422-1428.

Research output: Contribution to journal › Article › peer-review

Dietz, AC, Savage, SA, Vlachos, A, Mehta, PA, Bresters, D, Tolar, J, Bonfim, C, Dalle, JH, de la Fuente, J, Skinner, R, Boulad, F, Duncan, CN, Baker, KS, Pulsipher, MA, Lipton, JM, Wagner, JE & Alter, BP 2017, 'Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT', Biology of Blood and Marrow Transplantation, vol. 23, no. 9, pp. 1422-1428. https://doi.org/10.1016/j.bbmt.2017.05.022

Dietz AC, Savage SA, Vlachos A, Mehta PA, Bresters D, Tolar J et al. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biology of Blood and Marrow Transplantation. 2017 Sep;23(9):1422-1428. doi: 10.1016/j.bbmt.2017.05.022

Dietz, Andrew C. ; Savage, Sharon A. ; Vlachos, Adrianna et al. / Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes : Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 9. pp. 1422-1428.

@article{7b9f51785083457d9aaab237ae91172e,

title = "Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT",

abstract = "Patients with inherited bone marrow failure syndromes (IBMFS), such as Fanconi anemia (FA), dyskeratosis congenita (DC), or Diamond Blackfan anemia (DBA), can have hematologic manifestations cured through hematopoietic cell transplantation (HCT). Subsequent late effects seen in these patients arise from a combination of the underlying disease, the pre-HCT therapy, and the HCT process. During the international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium on late effects screening and recommendations following allogeneic hematopoietic cell transplantation for immune deficiency and nonmalignant hematologic diseases held in Minneapolis, Minnesota in May 2016, a half-day session was focused specifically on the unmet needs for these patients with IBMFS. This multidisciplinary group of experts in rare diseases and transplantation late effects has already published on the state of the science in this area, along with discussion of an agenda for future research. This companion article outlines consensus disease-specific long-term follow-up screening guidelines for patients with IMBFS.",

keywords = "Diamond Blackfan anemia, Dyskeratosis congenita, Fanconi anemia, Inherited bone marrow failure syndromes, Late effects, Pediatric allogeneic hematopoietic cell transplant",

author = "Dietz, {Andrew C.} and Savage, {Sharon A.} and Adrianna Vlachos and Mehta, {Parinda A.} and Dorine Bresters and Jakub Tolar and Carmem Bonfim and Dalle, {Jean Hugues} and {de la Fuente}, Josu and Roderick Skinner and Farid Boulad and Duncan, {Christine N.} and Baker, {K. Scott} and Pulsipher, {Michael A.} and Lipton, {Jeffrey M.} and Wagner, {John E.} and Alter, {Blanche P.}",

note = "Funding Information: Financial disclosure: This work was supported in part by grants from the National Institutes of Health (1R13CA159788-01, to M.A.P. and K.S.B.; U01HL069254, to M.A.P.; R01 CA078938, to K.S.B.; and 5R01HL079571, to J.M.L. and A.V.), the Pediatric Blood and Marrow Transplant Consortium, and St. Baldrick's Foundation (U01HL069254, to M.A.P.). B.P.A. and S.A.S. are supported by the Intramural Research Program of the National Cancer Institute. The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding. Funding Information: Financial disclosure: This work was supported in part by grants from the National Institutes of Health ( 1R13CA159788-01 , to M.A.P. and K.S.B.; U01HL069254 , to M.A.P.; R01 CA078938 , to K.S.B.; and 5R01HL079571 , to J.M.L. and A.V.), the Pediatric Blood and Marrow Transplant Consortium, and St. Baldrick's Foundation (U01HL069254, to M.A.P.). B.P.A. and S.A.S. are supported by the Intramural Research Program of the National Cancer Institute . The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: J.E.W. and B.P.A. contributed equally to this work. Publisher Copyright: {\textcopyright} 2017 The American Society for Blood and Marrow Transplantation",

year = "2017",

month = sep,

doi = "10.1016/j.bbmt.2017.05.022",

language = "English (US)",

volume = "23",

pages = "1422--1428",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes

T2 - Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT

AU - Dietz, Andrew C.

AU - Savage, Sharon A.

AU - Vlachos, Adrianna

AU - Mehta, Parinda A.

AU - Bresters, Dorine

AU - Tolar, Jakub

AU - Bonfim, Carmem

AU - Dalle, Jean Hugues

AU - de la Fuente, Josu

AU - Skinner, Roderick

AU - Boulad, Farid

AU - Duncan, Christine N.

AU - Baker, K. Scott

AU - Pulsipher, Michael A.

AU - Lipton, Jeffrey M.

AU - Wagner, John E.

AU - Alter, Blanche P.

N1 - Funding Information: Financial disclosure: This work was supported in part by grants from the National Institutes of Health (1R13CA159788-01, to M.A.P. and K.S.B.; U01HL069254, to M.A.P.; R01 CA078938, to K.S.B.; and 5R01HL079571, to J.M.L. and A.V.), the Pediatric Blood and Marrow Transplant Consortium, and St. Baldrick's Foundation (U01HL069254, to M.A.P.). B.P.A. and S.A.S. are supported by the Intramural Research Program of the National Cancer Institute. The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding. Funding Information: Financial disclosure: This work was supported in part by grants from the National Institutes of Health ( 1R13CA159788-01 , to M.A.P. and K.S.B.; U01HL069254 , to M.A.P.; R01 CA078938 , to K.S.B.; and 5R01HL079571 , to J.M.L. and A.V.), the Pediatric Blood and Marrow Transplant Consortium, and St. Baldrick's Foundation (U01HL069254, to M.A.P.). B.P.A. and S.A.S. are supported by the Intramural Research Program of the National Cancer Institute . The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: J.E.W. and B.P.A. contributed equally to this work. Publisher Copyright: © 2017 The American Society for Blood and Marrow Transplantation

PY - 2017/9

Y1 - 2017/9

N2 - Patients with inherited bone marrow failure syndromes (IBMFS), such as Fanconi anemia (FA), dyskeratosis congenita (DC), or Diamond Blackfan anemia (DBA), can have hematologic manifestations cured through hematopoietic cell transplantation (HCT). Subsequent late effects seen in these patients arise from a combination of the underlying disease, the pre-HCT therapy, and the HCT process. During the international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium on late effects screening and recommendations following allogeneic hematopoietic cell transplantation for immune deficiency and nonmalignant hematologic diseases held in Minneapolis, Minnesota in May 2016, a half-day session was focused specifically on the unmet needs for these patients with IBMFS. This multidisciplinary group of experts in rare diseases and transplantation late effects has already published on the state of the science in this area, along with discussion of an agenda for future research. This companion article outlines consensus disease-specific long-term follow-up screening guidelines for patients with IMBFS.

AB - Patients with inherited bone marrow failure syndromes (IBMFS), such as Fanconi anemia (FA), dyskeratosis congenita (DC), or Diamond Blackfan anemia (DBA), can have hematologic manifestations cured through hematopoietic cell transplantation (HCT). Subsequent late effects seen in these patients arise from a combination of the underlying disease, the pre-HCT therapy, and the HCT process. During the international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium on late effects screening and recommendations following allogeneic hematopoietic cell transplantation for immune deficiency and nonmalignant hematologic diseases held in Minneapolis, Minnesota in May 2016, a half-day session was focused specifically on the unmet needs for these patients with IBMFS. This multidisciplinary group of experts in rare diseases and transplantation late effects has already published on the state of the science in this area, along with discussion of an agenda for future research. This companion article outlines consensus disease-specific long-term follow-up screening guidelines for patients with IMBFS.

KW - Diamond Blackfan anemia

KW - Dyskeratosis congenita

KW - Fanconi anemia

KW - Inherited bone marrow failure syndromes

KW - Late effects

KW - Pediatric allogeneic hematopoietic cell transplant

UR - http://www.scopus.com/inward/record.url?scp=85021301439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021301439&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.05.022

DO - 10.1016/j.bbmt.2017.05.022

M3 - Article

C2 - 28533057

AN - SCOPUS:85021301439

VL - 23

SP - 1422

EP - 1428

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this